Bioequivalence guidance accessibility
Executive Summary
FDA releases draft guidance regarding the agency's plans to make product-specific, bioequivalence study design guidance available to the public on FDA's Web site. Currently, ANDA applicants must request guidance from the agency and wait for a response. The agency is seeking public comments for product-specific bioequivalence recommendations. FDA's Office of Generic Drugs has touted this long-awaited guidance as a means to reduce correspondence (1"The Pink Sheet" March 26, 2007, p. 14)...
You may also be interested in...
FDA Draft Bioequivalence Guidance Draws Litany Of Brand Name Complaints
Brand firms are weighing in on product-specific draft guidance issued by FDA, which the agency hopes will allow generic drug firms to design bioequivalence studies for their ANDAs without having to consult with the Office of Generic Drugs (1"The Pink Sheet" June 11, 2007, In Brief). The draft guidances can be found on 2FDA's Web site
ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources
FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.